Patient Counseling | BEXSERO (Meningococcal Group B Vaccine) HCP

Incorporate a meningitis B (MenB) conversation into your protocol to help ensure you vaccinate all appropriate patients

Follow a simple, 3-step plan of action:

EDUCATE patients about meningococcal disease, the 5 vaccine-preventable serogroups, and how BEXSERO can help protect against MenB^1-3,*

START the BEXSERO 2-dose vaccination series for your appropriate patients³

SCHEDULE the second dose; send follow-up reminders to help patients complete the series

*The AAP encourages discussion about the availability of MenB vaccines with families. The discussion and decision should be documented even if the vaccine is not administered.⁴

INDICATION & IMPORTANT SAFETY INFO

INDICATION

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

IMPORTANT SAFETY INFORMATION FOR BEXSERO

BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO

BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO
Appropriate observation and medical treatment should always be readily available in case of an anaphylactic reaction following the administration of the vaccine
The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions
Syncope (fainting) can occur in association with administration of BEXSERO. Ensure procedures are in place to avoid injury from falling associated with syncope
The most common solicited adverse reactions observed in clinical trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%)
Vaccination with BEXSERO may not provide protection against all meningococcal serogroup B strains
Some individuals with altered immunocompetence may have reduced immune responses to BEXSERO
Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with BEXSERO
Vaccination with BEXSERO may not result in protection in all vaccine recipients

Please see full Prescribing Information for BEXSERO.

YOUR PATIENTS ARE COUNTING ON YOU TO START THE CONVERSATION

Incorporate a meningitis B (MenB) conversation into your protocol to help ensure you vaccinate all appropriate patients

Successfully complete every patient’s MenB series

Kim “I Survived”

BEXSERO CPT CODE: 90620